Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Trial Profile

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2018

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms Dapa-HF
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Oct 2018 Planned End Date changed from 5 Dec 2019 to 4 Dec 2019.
    • 12 Oct 2018 Planned primary completion date changed from 5 Dec 2019 to 4 Dec 2019.
    • 27 Aug 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top